HRP20211965T1 - Novi selektivni inhibitori jak1 i njihova upotreba - Google Patents
Novi selektivni inhibitori jak1 i njihova upotreba Download PDFInfo
- Publication number
- HRP20211965T1 HRP20211965T1 HRP20211965TT HRP20211965T HRP20211965T1 HR P20211965 T1 HRP20211965 T1 HR P20211965T1 HR P20211965T T HRP20211965T T HR P20211965TT HR P20211965 T HRP20211965 T HR P20211965T HR P20211965 T1 HRP20211965 T1 HR P20211965T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- imidazo
- nrr
- pyridin
- pharmaceutically acceptable
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 101150079478 jak1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- JVWXVJOIUKQBOJ-NWDGAFQWSA-N 2-[(2R,5S)-5-(4-methyl-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl)oxan-2-yl]acetonitrile Chemical compound CC1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@@H](OC1)CC#N JVWXVJOIUKQBOJ-NWDGAFQWSA-N 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- UDGHPISWLBXGGY-WDEREUQCSA-N 2-[(2R,5S)-5-[4-(hydroxymethyl)-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl]oxan-2-yl]acetonitrile Chemical compound OCC1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@@H](OC1)CC#N UDGHPISWLBXGGY-WDEREUQCSA-N 0.000 claims 3
- ZFQNHUSKKDBFHY-GRYCIOLGSA-N 2-[(2R,5S)-5-[4-[(1R)-1-hydroxyethyl]-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl]oxan-2-yl]acetonitrile Chemical compound O[C@H](C)C1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@@H](OC1)CC#N ZFQNHUSKKDBFHY-GRYCIOLGSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- -1 oxonium tetrafluoroborate Chemical compound 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 238000005984 hydrogenation reaction Methods 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
- ABAUJVSEICFAOS-NWDGAFQWSA-N 2-[(2R,5S)-5-(4-ethyl-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl)oxan-2-yl]acetonitrile Chemical compound C(C)C1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@@H](OC1)CC#N ABAUJVSEICFAOS-NWDGAFQWSA-N 0.000 claims 1
- UDGHPISWLBXGGY-QWRGUYRKSA-N 2-[(2S,5S)-5-[4-(hydroxymethyl)-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl]oxan-2-yl]acetonitrile Chemical compound OCC1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@H](OC1)CC#N UDGHPISWLBXGGY-QWRGUYRKSA-N 0.000 claims 1
- WKNNRZVOWSSOSY-XYPYZODXSA-N C12=C(C3=C(N=C(N3[C@H]3CC[C@@H](CC3)C#N)CO)C=N2)OC=C1 Chemical compound C12=C(C3=C(N=C(N3[C@H]3CC[C@@H](CC3)C#N)CO)C=N2)OC=C1 WKNNRZVOWSSOSY-XYPYZODXSA-N 0.000 claims 1
- HIQALKYWCDEOTH-IJLUTSLNSA-N C12=C(N=CC=3N=C(N(C1=3)[C@H]1CC[C@@H](CC1)C#N)[C@@H](C)O)C=CO2 Chemical compound C12=C(N=CC=3N=C(N(C1=3)[C@H]1CC[C@@H](CC1)C#N)[C@@H](C)O)C=CO2 HIQALKYWCDEOTH-IJLUTSLNSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- WWFMBYPVXNSPOA-JHJVBQTASA-N O1C=CC2=C1C=1N(C(=NC=1C=N2)[C@H](O)C)[C@H]1CC[C@@H](CC1)CC#N Chemical compound O1C=CC2=C1C=1N(C(=NC=1C=N2)[C@H](O)C)[C@H]1CC[C@@H](CC1)CC#N WWFMBYPVXNSPOA-JHJVBQTASA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 claims 1
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403660P | 2016-10-03 | 2016-10-03 | |
| EP17858944.6A EP3509591B1 (en) | 2016-10-03 | 2017-09-30 | Novel jak1 selective inhibitors and uses thereof |
| PCT/US2017/054668 WO2018067422A1 (en) | 2016-10-03 | 2017-09-30 | Novel jak1 selective inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211965T1 true HRP20211965T1 (hr) | 2022-03-18 |
Family
ID=61831161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211965TT HRP20211965T1 (hr) | 2016-10-03 | 2017-09-30 | Novi selektivni inhibitori jak1 i njihova upotreba |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | USRE49834E1 (enExample) |
| EP (1) | EP3509591B1 (enExample) |
| JP (1) | JP7089141B2 (enExample) |
| KR (1) | KR102399848B1 (enExample) |
| CN (2) | CN113214278B (enExample) |
| AU (3) | AU2017339417C1 (enExample) |
| DK (1) | DK3509591T3 (enExample) |
| EA (1) | EA201990523A1 (enExample) |
| ES (1) | ES2901216T3 (enExample) |
| HK (1) | HK1253040A1 (enExample) |
| HR (1) | HRP20211965T1 (enExample) |
| HU (1) | HUE058120T2 (enExample) |
| IL (3) | IL265358B (enExample) |
| MX (1) | MX390005B (enExample) |
| NZ (1) | NZ751284A (enExample) |
| PL (1) | PL3509591T3 (enExample) |
| PT (1) | PT3509591T (enExample) |
| RS (1) | RS62695B1 (enExample) |
| WO (1) | WO2018067422A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3509591T3 (da) | 2016-10-03 | 2021-12-20 | Highlightll Pharmaceutical Hainan Co Ltd | Nye jak1-selektive inhibitorer og anvendelser deraf |
| RU2019125177A (ru) * | 2017-01-11 | 2021-02-15 | Лео Фарма А/С | Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение |
| IL282643B2 (en) * | 2018-10-31 | 2025-08-01 | Incyte Corp | A selective jak1 inhibitor for use in a method of treating hematological disease |
| JP2022524997A (ja) | 2019-03-05 | 2022-05-11 | インサイト・コーポレイション | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
| JP2022526301A (ja) | 2019-03-19 | 2022-05-24 | インサイト・コーポレイション | 尋常性白斑のバイオマーカー |
| JP7628967B2 (ja) * | 2019-06-06 | 2025-02-12 | ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド | フロイミダゾピリジン化合物、多形物質および塩の多形物質の合成方法 |
| CN113906035B (zh) | 2019-06-06 | 2023-11-10 | 杭州高光制药有限公司 | 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 |
| CN115803317B (zh) | 2020-05-19 | 2025-07-15 | 拜耳作物科学股份公司 | 作为杀真菌化合物的氮杂双环(硫代)酰胺 |
| JP7729845B2 (ja) | 2020-06-10 | 2025-08-26 | バイエル、アクチエンゲゼルシャフト | 新規殺菌剤としてのアザビシクリル置換複素環 |
| WO2022260945A1 (en) * | 2021-06-07 | 2022-12-15 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| JP2024543198A (ja) * | 2021-09-13 | 2024-11-19 | ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド | 中枢神経障害を治療する方法 |
| CN114213424B (zh) | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
| WO2025224600A1 (en) * | 2024-04-21 | 2025-10-30 | Biohaven Therapeutics Ltd. | Treatment of alpha-synucleinopathies and neuroprotection |
| WO2025248468A1 (en) | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria) |
| WO2026002028A1 (zh) * | 2024-06-26 | 2026-01-02 | 杭州多域生物技术有限公司 | 稠杂芳环类化合物、其药物组合物及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| ATE66143T1 (de) | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| CA2338780C (en) | 1998-07-28 | 2007-01-02 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing medicinal substance at targeted site in intestine |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| EP1720855A4 (en) | 2004-03-02 | 2008-12-17 | Smithkline Beecham Corp | HEMMER OF ACT ACTIVITY |
| CN101277965A (zh) * | 2005-08-04 | 2008-10-01 | 西特里斯药业公司 | 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物 |
| JP2013505965A (ja) * | 2009-09-29 | 2013-02-21 | エックスカバリー ホールディング カンパニー エルエルシー | Ｐｉ３ｋ（デルタ）選択的阻害剤 |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| EP2624698A4 (en) | 2010-10-08 | 2014-10-08 | Abbvie Inc | Furo [3,2-D] PYRIMIDINE COMPOUNDS |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| RU2632870C2 (ru) | 2011-08-12 | 2017-10-11 | Ниссан Кемикал Индастриз, Лтд. | Трициклические гетероциклические соединения и ингибиторы jak |
| MX2015005428A (es) * | 2012-11-01 | 2015-07-21 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak). |
| US20150118229A1 (en) | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| JP2017514832A (ja) | 2014-04-30 | 2017-06-08 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ１抑制剤を調製する方法及びその新しい形態 |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| DK3509591T3 (da) | 2016-10-03 | 2021-12-20 | Highlightll Pharmaceutical Hainan Co Ltd | Nye jak1-selektive inhibitorer og anvendelser deraf |
-
2017
- 2017-09-30 DK DK17858944.6T patent/DK3509591T3/da active
- 2017-09-30 US US17/526,799 patent/USRE49834E1/en active Active
- 2017-09-30 ES ES17858944T patent/ES2901216T3/es active Active
- 2017-09-30 AU AU2017339417A patent/AU2017339417C1/en active Active
- 2017-09-30 PL PL17858944T patent/PL3509591T3/pl unknown
- 2017-09-30 MX MX2019003649A patent/MX390005B/es unknown
- 2017-09-30 CN CN202110514751.5A patent/CN113214278B/zh active Active
- 2017-09-30 RS RS20211521A patent/RS62695B1/sr unknown
- 2017-09-30 HR HRP20211965TT patent/HRP20211965T1/hr unknown
- 2017-09-30 PT PT178589446T patent/PT3509591T/pt unknown
- 2017-09-30 US US16/333,994 patent/US10738060B2/en not_active Ceased
- 2017-09-30 EA EA201990523A patent/EA201990523A1/ru unknown
- 2017-09-30 EP EP17858944.6A patent/EP3509591B1/en active Active
- 2017-09-30 HU HUE17858944A patent/HUE058120T2/hu unknown
- 2017-09-30 CN CN201780004442.5A patent/CN108366994B/zh active Active
- 2017-09-30 WO PCT/US2017/054668 patent/WO2018067422A1/en not_active Ceased
- 2017-09-30 JP JP2019517991A patent/JP7089141B2/ja active Active
- 2017-09-30 HK HK18112420.5A patent/HK1253040A1/zh unknown
- 2017-09-30 NZ NZ751284A patent/NZ751284A/en unknown
- 2017-09-30 KR KR1020197009016A patent/KR102399848B1/ko active Active
-
2019
- 2019-03-13 IL IL265358A patent/IL265358B/en unknown
-
2022
- 2022-02-17 AU AU2022201058A patent/AU2022201058B2/en active Active
- 2022-02-17 AU AU2022201061A patent/AU2022201061B2/en active Active
- 2022-03-10 IL IL291265A patent/IL291265B2/en unknown
- 2022-03-10 IL IL291267A patent/IL291267B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211965T1 (hr) | Novi selektivni inhibitori jak1 i njihova upotreba | |
| AU2022206693B2 (en) | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor | |
| JP2019537559A5 (enExample) | ||
| EP3510033B1 (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| JP7171444B2 (ja) | ウイルス感染治療用のジヒドロピラノピリミジン | |
| RU2011121876A (ru) | Пиразолопиримидиновые соединения-ингибиторы jak и способы | |
| EA201390199A1 (ru) | 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение | |
| PH12015500294B1 (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
| EA201490579A1 (ru) | Новые хиральные n-ацил-5,6,7,(8-замещенные)тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез | |
| HRP20170017T1 (hr) | Inhibitori tirozin kinaze | |
| CA2953798A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| HRP20170447T1 (hr) | Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini | |
| UA102088C2 (ru) | Производные n-азабициклических карбоксамидов, их получение и применение в терапии | |
| SG195085A1 (en) | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors | |
| UA102837C2 (ru) | Производные азабициклических карбоксамидов, их получение и их применение в терапии | |
| AR065333A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| TW201524983A (zh) | 螺氧基吲哚衍生物之製造方法 | |
| AR058151A1 (es) | Compuestos antagosnistas de los receptores 2 de dopamina de rapida disociacion | |
| HRP20090394T1 (hr) | 2-ALKINIL- I 2-ALKENILPIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINSKI ANTAGONISTI ADENOZINSKOG RECEPTORA A2A | |
| MX2021014320A (es) | Metodo para sintetizar el compuesto de furoimidazopiridina, sustancia polimorfica y sustancia polimorfica de sal. | |
| HRP20150697T1 (hr) | Derivati azaindola kao inhibitori proteina kinaze abi i src | |
| ES2616883T3 (es) | Derivados amida heterocíclicos como antagonistas del receptor P2X7 | |
| ES2729490T3 (es) | Derivados de isoindolina | |
| MX2024006688A (es) | Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo. | |
| MX2015016976A (es) | Preparacion de 4-((1r,2s,5r)-6-(benciloxi)-7-oxo-1,6-diazabiciclo[ 3.2.1]octano-2-carboxamido)piperidin-1-carboxilato de ter-butilo. |